Search

Purpose: To develop an independent log file–based intensity‐modulated radiation therapy (IMRT) quality assurance (QA) tool for the 0.35 T magnetic resonance‐linac (MR‐linac) and investigate the ability of various IMRT plan complexity metrics to predict the QA results. Complexity metrics related to tissue heterogeneity were also introduced. Methods: The tool for particle simulation (TOPAS) Monte Carlo code was utilized with a previously validated linac head model. A cohort of 29 treatment plans was selected for IMRT QA using the developed QA tool and the vendor‐supplied adaptive QA (AQA) tool. For 27 independent patient cases, various IMRT plan complexity metrics were calculated to assess the deliverability of these plans. A correlation between the gamma pass rates (GPRs) from the AQA results and calculated IMRT complexity metrics was determined using the Pearson correlation coefficients. Tissue heterogeneity complexity metrics were calculated based on the gradient of the Hounsfield units. Results: The median and interquartile range for the TOPAS GPRs (3%/3 mm criteria) were 97.24% and 3.75%, respectively, and were 99.54% and 0.36% for the AQA tool, respectively. The computational time for TOPAS ranged from 4 to 8 h to achieve a statistical uncertainty of <1.5%, whereas the AQA tool had an average calculation time of a few minutes. Of the 23 calculated IMRT plan complexity metrics, the AQA GPRs had correlations with 7 out of 23 of the calculated metrics. Strong correlations (|r| > 0.7) were found between the GPRs and the heterogeneity complexity metrics introduced in this work. Conclusions: An independent MC and log file–based IMRT QA tool was successfully developed and can be clinically deployed for offline QA. The complexity metrics will supplement QA reports and provide information regarding plan complexity. [ABSTRACT FROM AUTHOR]

Image-guided radiotherapy (IGRT) enables optimal tumor targeting and sparing of organs-at-risk, which ultimately results in improved outcomes for patients. Magnetic resonance imaging (MRI) revolutionized diagnostic imaging with its superior soft tissue contrast, high spatiotemporal resolution, and freedom from ionizing radiation exposure. Over the past few years there has been burgeoning interest in MR-guided radiotherapy (MRgRT) to overcome current challenges in X-ray-based IGRT, including but not limited to, suboptimal soft tissue contrast, lack of efficient daily adaptation, and incremental exposure to ionizing radiation. In this review, we present an overview of the technologic advancements in IGRT that led to MRI-linear accelerator (MRL) integration. Our report is organized in three parts: (1) a historical timeline tracing the origins of radiotherapy and evolution of IGRT, (2) currently available MRL technology, and (3) future directions and aspirations for MRL applications. [ABSTRACT FROM AUTHOR]

Advances in image-guided radiotherapy have brought about improved oncologic outcomes and reduced toxicity. The next generation of image guidance in the form of magnetic resonance imaging (MRI) will improve visualization of tumors and make radiation treatment adaptation possible. In this review, we discuss the role that MRI plays in radiotherapy, with a focus on the integration of MRI with the linear accelerator. The MR linear accelerator (MR-Linac) will provide real-time imaging, help assess motion management, and provide online adaptive therapy. Potential advantages and the current state of these MR-Linacs are highlighted, with a discussion of six different clinical scenarios, leading into a discussion on the future role of these machines in clinical workflows. [ABSTRACT FROM AUTHOR]

Background: To define the location of the initial contralateral lymph node (LN) metastasis in patients with oropharynx cancer. Methods: The location of the LN centroids from patients with oropharynx cancer and a single radiographically positive contralateral LN was defined. A clinical target volume (CTV) inclusive of all LN centroids was created, and its impact on dose to organs at risk was assessed. Results: We identified 55 patients of which 49/55 had a single contralateral LN in level IIA, 4/55 in level III, 1/55 in level IIB, and 1/55 in the retropharynx. Mean radiation dose to the contralateral parotid gland was 15.1 and 21.0 Gy, (p <0.001) using the modeled high‐risk elective CTV and a consensus CTV, respectively. Conclusions: We present a systematic approach for identifying the contralateral nodal regions at highest risk of harboring subclinical disease in patients with oropharynx cancer that warrants prospective clinical study. [ABSTRACT FROM AUTHOR]

Byline: Yue. Yan, Poonam. Yadav, Michael. Bassetti, Kaifang. Du, Daniel. Saenz, Paul. Harari, Bhudatt. Paliwal This study investigated the dosimetric differences in treatment plans from flattened and flattening filter-free (FFF) [...]

Purpose: The aim of this work was to develop and benchmark a magnetic resonance (MR)‐guided linear accelerator head model using the GEANT4 Monte Carlo (MC) code. The validated model was compared to the treatment planning system (TPS) and was also used to quantify the electron return effect (ERE) at a lung–water interface. Methods: The average energy, including the spread in the energy distribution, and the radial intensity distribution of the incident electron beam were iteratively optimized in order to match the simulated beam profiles and percent depth dose (PDD) data to measured data. The GEANT4 MC model was then compared to the TPS model using several photon beam tests including oblique beams, an off‐axis aperture, and heterogeneous phantoms. The benchmarked MC model was utilized to compute output factors (OFs) with the 0.35 T magnetic field turned on and off. The ERE was quantified at a lung–water interface by simulating PDD curves with and without the magnetic field for 6.6 × 6.6 cm2 and 2.5 × 2.5 cm2 field sizes. A 2%/2 mm gamma criterion was used to compare the MC model with the TPS data throughout this study. Results: The final incident electron beam parameters were 6.0 MeV average energy with a 1.5 MeV full width at half maximum (FWHM) Gaussian energy spread and a 1.0 mm FWHM Gaussian radial intensity distribution. The MC‐simulated OFs were found to be in agreement with the TPS‐calculated and measured OFs, and no statistical difference was observed between the 0.35 T and 0.0 T OFs. Good agreement was observed between the TPS‐calculated and MC‐simulated data for the photon beam tests with gamma pass rates ranging from 96% to 100%. An increase of 4.3% in the ERE was observed for the 6.6 × 6.6 cm2 field size relative to the 2.5 × 2.5 cm2 field size. The ratio of the 0.35 T PDD to the 0.0 T PDD was found to be up to 1.098 near lung–water interfaces for the 6.6 × 6.6 cm2 field size using the MC model. Conclusions: A vendor‐independent Monte Carlo model has been developed and benchmarked for a 0.35 T/6 MV MR‐linac. Good agreement was obtained between the GEANT4 and TPS models except near heterogeneity interfaces. [ABSTRACT FROM AUTHOR]

Background: Prostate cancer is one of the most common solid malignancies and has a high morbidity rate. The uncertainty of the prostate location compromises the overall treatment plan optimisation. To account for the location uncertainty, the radiation oncologist needs to expand the margin of the planning target volume (PTV), which may increase the radiation toxicity to organs in proximity. Materials and methods: In this study, we investigated the quality of treatment plans for a patient with different ring sizes (2 and 3 cm). A small ring-shaped structure circumferentially around the PTV helps in defining the location of PTV. Prostate and pelvic node plans were analysed with dose prescription to 99% of PTV. Results: Additional ring-shaped structures led to more conformal dose coverage for target with reduced radiation side effects to nearby organ at risk (OAR). Expected treatment time was slightly higher for 2 cm ring compared to 3 cm ring. In case of prostate, expected duration was 4% higher, while for node plan, expected duration for 2 cm ring was 16% higher compared to 3 cm ring plan. Conclusions: It was observed that using a smaller size ring can lead to improved dose sparing to OAR with same target coverage as with larger dimension ring. The composite plans do not show any clinically significant difference in dose to OARs. [ABSTRACT FROM AUTHOR]

Purpose: Dark current radiation produced during linac beam‐hold has the potential to lead to unplanned dose delivered to the patient. With the increased usage of motion management and step‐and‐shoot IMRT deliveries for MR‐guided systems leading to increased beam‐hold time, it is necessary to consider the impact of dark current radiation on patient treatments. Methods: The relative dose rate due to dark current for the ViewRay MRIdian linac was measured longitudinally over 15 months (June 2018‐August 2019). Ion chamber measurements were acquired with the linac in the beam‐hold state and the beam‐on state, with the ratio representing the relative dark current dose rate. The potential contribution of the dark current dose to the overall prescription was retrospectively analyzed for 972 fractions from 83 patients over the same time period. The amount of time spent in the beam‐hold state was combined with the monthly measured relative dark current dose rate to estimate the dark current dose contribution. Results: The relative dark current dose rate compared to the beam‐on dose rate was 0.12% ± 0.027%. In a near worst‐case estimation, the dark current dose contribution accounted for 0.90% ± 0.67% of the prescription dose across all fractions (3.61% maximum). Gantry and MLC motion between segments accounted for 87% of the dark current contribution, with the remaining 13% attributable to gating during segment delivery. The largest dark current contributions were associated with plans delivering a small dose per treatment segment. Conclusions: The dark current associated with new clinical treatment units should be considered prior to treatment delivery to ensure it will not lead to dosimetric inaccuracies. For the MRIdian linac system investigated in this work, the contribution from dark current remained relatively low, though users should be cognizant of the larger potential dosimetric contribution for plans with small doses per segment. [ABSTRACT FROM AUTHOR]

Purpose: With advance magnetic resonance (MR)‐guided online adaptive radiotherapy (MRgoART) relying on calculation‐based intensity‐modulated radiation therapy (IMRT) quality assurance (QA), accurate and sensitive QA of the multileaf collimator (MLC) becomes an increasingly essential component for routine machine QA. As such, it is important to assure compliance with the AAPM TG142 guidelines to supplement calculation‐based QA methods for an online adaptive radiotherapy program. We have developed and implemented an efficient and highly sensitive QA procedure using an ionization chamber profiler (ICP) array to enable real‐time characterization of the positional accuracy of a double‐focused and double‐stacked MLC on a clinical MR‐guided radiotherapy (MRgRT) system and to supplement calculation‐based QA for an MRgoART program. Methods: An in‐house MR‐compatible jig was used to position the ICP (detector resolution 5 mm on X/Y axis) at an extended SDD of 108.4 cm to enable each MLC leaf (8.3 mm leaf width at isocenter) to be uniquely determined by two neighboring ion chambers. The MRgRT linac system utilizes a novel jawless, double‐focused, and double‐stacked MLC design such that the upper bank (MLC1) and lower bank (MLC2) are offset by half a leaf width. Positional accuracy was characterized by three methods: single bank half‐beam block (HBB) at central axis, forward slash diagonal (FSD), and backslash diagonal (BSD) at off‐axis. Measurements were performed for each bank in which each leaf occludes half of a detector. A corresponding reference field with the MLC retracted from occlusion was measured. The sensitivities of HBB, FSD, and BSD were evaluated by introducing 0.5–2.5 mm of known errors in 0.5 mm increments, in both positive and negative directions. The relationship between detector response and MLC error was established. Over a 6‐month longitudinal assessment, we have evaluated MLC performance with weekly QA of HBB among cardinal angles, and monthly QA of FSD and BSD. Results: A strong correlation was found between detector response of percentage dose difference and MLC positional error introduced (N = 350 introduced errors) for both HBB and FSD/BSD with coefficient of determination of 0.999 and 0.977, respectively. The relationship between detector response to MLC positional change was found to be 20.65%/mm for HBB and 11.14%/mm for FSD and BSD. At baseline, the mean MLC positional accuracy averaged across all leaves was 0.06 ± 0.27 mm (HBB), 0.04 ± 0.52 mm (FSD), −0.06 ± 0.51 mm (BSD). The mean MLC positional accuracy relative to baseline over the 6‐month assessment was found to be highly reproducible at 0.00 ± 0.12 mm (HBB; N = 28 weeks), −0.02 ± 0.19 mm (FSD; N = 6 months), −0.03 ± 0.19 mm (BSD; N = 6 months). Conclusions: Positional accuracy of a novel jawless, double‐focused, double‐stacked MLC has been characterized and monitored over 6 months with an efficient, highly sensitive, and robust method using an ICP array. This routine QA method supplements calculation‐based IMRT QA for an online adaptive radiotherapy program. Longitudinal assessment demonstrated no‐drift in the MLC calibration. A highly reproducible jig setup allowed the validation of MLC positional accuracy to be within TG142 criteria of ±1 mm for 99% of measurements (i.e., 100% HBB, 95% BSD, 95% FSD) over the 6‐month assessment. [ABSTRACT FROM AUTHOR]

Purpose: With the increasing use of MR‐guided radiation therapy (MRgRT), it becomes important to understand and explore accuracy of medical dosimeters in the presence of magnetic field. The purpose of this work is to characterize metal‐oxide‐semiconductor field‐effect transistors (MOSFETs) in MRgRT systems at 0.345 T magnetic field strength. Methods: A MOSFET dosimetry system, developed by Best Medical Canada for in‐vivo patient dosimetry, was used to study various commissioning tests performed on a MRgRT system, MRIdian® Linac. We characterized the MOSFET dosimeter with different cable lengths by determining its calibration factor, monitor unit linearity, angular dependence, field size dependence, percentage depth dose (PDD) variation, output factor change, and intensity modulated radiation therapy quality assurance (IMRT QA) verification for several plans. MOSFET results were analyzed and compared with commissioning data and Monte Carlo calculations. Results: MOSFET measurements were not found to be affected by the presence of 0.345 T magnetic field. Calibration factors were similar for different cable length dosimeters either placed at the parallel or perpendicular direction to the magnetic field, with variations of less than 2%. The detector showed good linearity (R2 = 0.999) for 100–600 MUs range. Output factor measurements were consistent with ionization chamber data within 2.2%. MOSFET PDD measurements were found to be within 1% for 1–15 cm depth range in comparison to ionization chamber. MOSFET normalized angular response matched thermoluminescent detector (TLD) response within 5.5%. The IMRT QA verification data for the MRgRT linac showed that the percentage difference between ionization chamber and MOSFET was 0.91%, 2.05%, and 2.63%, respectively for liver, spine, and mediastinum. Conclusion: MOSFET dosimeters are not affected by the 0.345 T magnetic field in MRgRT system. They showed physics parameters and performance comparable to TLD and ionization chamber; thus, they constitute an alternative to TLD for real‐time in‐vivo dosimetry in MRgRT procedures. [ABSTRACT FROM AUTHOR]

Purpose: To describe and characterize daily machine quality assurance (QA) for an MR‐guided radiotherapy (MRgRT) linac system, in addition to reporting a longitudinal assessment of the dosimetric and mechanical stability over a 7‐month period of clinical operation. Methods: Quality assurance procedures were developed to evaluate MR imaging/radiation isocenter, imaging and patient handling system, and linear accelerator stability. A longitudinal assessment was characterized for safety interlocks, laser and imaging isocenter coincidence, imaging and radiation (RT) isocentricity, radiation dose rate and output, couch motion, and MLC positioning. A cylindrical water phantom and an MR‐compatible A1SL detector were utilized. MR and RT isocentricity and MLC positional accuracy was quantified through dose measured with a 0.40 cm2 x 0.83 cm2 field at each cardinal angle. The relationship between detector response to MR/RT isocentricity and MLC positioning was established through introducing known errors in phantom position. Results: Correlation was found between detector response and introduced positional error (N = 27) with coefficients of determination of 0.9996 (IEC‐X), 0.9967 (IEC‐Y), 0.9968 (IEC‐Z) in each respective shift direction. The relationship between dose (DoseMR/RT+MLC) and the vector magnitude of MLC and MR/RT positional error (Errormag) was calculated to be a nonlinear response and resembled a quadratic function: DoseMR/RT+MLC[%] = −0.0253 Errormag [mm]2 − 0.0195 Errormag [mm]. For the temporal assessment (N = 7 months), safety interlocks were functional. Laser coincidence to MR was within ±2.0 mm (99.6%) and ±1.0 mm (86.8%) over the 7‐month assessment. IGRT position–reposition shifts were within ±2.0 mm (99.4%) and ±1.0 mm (92.4%). Output was within ±3% (99.4%). Mean MLC and MR/RT isocenter accuracy was 1.6 mm, averaged across cardinal angles for the 7‐month period. Conclusions: The linac and IGRT accuracy of an MR‐guided radiotherapy system has been validated and monitored over seven months for daily QA. Longitudinal assessment demonstrated a drift in dose rate, but temporal assessment of output, MLC position, and isocentricity has been stable. [ABSTRACT FROM AUTHOR]

Background: Stereotactic body radiation therapy (SBRT) given in 1-5 fractions is an effective treatment for vertebral metastases. Real-time magnetic resonance-guided radiotherapy (MRgRT) improves soft tissue contrast, which translates into accurate delivery of spine SBRT. Here we report on clinical implementation of MRgRT for spine SBRT, the quality of MRgRT plans compared to TrueBeam based volumetric modulated arc therapy (VMAT) plans in the treatment of spine metastases and benefits of MRgRT MR scan. Patients and methods: Ten metastatic lesions were included in this study for plan comparison. Lesions were spread across thoracic spine and lumbosacral spine. Three fraction spine SBRT plans: 27Gy to planning target volume (PTV) and 30Gy to gross tumor volume (GTV) were generated on the ViewRay MRIdian Linac system and compared to TrueBeamTM STx based VMAT plans. Plans were compared using metrics such as minimum dose, maximum dose, mean dose, ratio of the dose to 50% of the volume (R50), conformity index, homogeneity index and dose to the spinal cord. Results: MRIdian plans achieved equivalent target coverage and spinal cord dose compared to VMAT plans. The maximum and minimum PTV doses and homogeneity index were equivalent for both planning systems. R50 was lower for MRIdian plans compared to VMAT plans, indicating a lower spread of intermediate doses with MRIdian system (5.16 vs. 6.11, p = 0.03). Conclusions: MRgRT can deliver high-quality spine SBRT plans comparable to TrueBeam volumetric modulated arc therapy (VMAT) plans. [ABSTRACT FROM AUTHOR]

Purpose: To develop and evaluate the feasibility of deep learning approaches for MR‐based treatment planning (deepMTP) in brain tumor radiation therapy. Methods and materials: A treatment planning pipeline was constructed using a deep learning approach to generate continuously valued pseudo CT images from MR images. A deep convolutional neural network was designed to identify tissue features in volumetric head MR images training with co‐registered kVCT images. A set of 40 retrospective 3D T1‐weighted head images was utilized to train the model, and evaluated in 10 clinical cases with brain metastases by comparing treatment plans using deep learning generated pseudo CT and using an acquired planning kVCT. Paired‐sample Wilcoxon signed rank sum tests were used for statistical analysis to compare dosimetric parameters of plans made with pseudo CT images generated from deepMTP to those made with kVCT‐based clinical treatment plan (CTTP). Results: deepMTP provides an accurate pseudo CT with Dice coefficients for air: 0.95 ± 0.01, soft tissue: 0.94 ± 0.02, and bone: 0.85 ± 0.02 and a mean absolute error of 75 ± 23 HU compared with acquired kVCTs. The absolute percentage differences of dosimetric parameters between deepMTP and CTTP was 0.24% ± 0.46% for planning target volume (PTV) volume, 1.39% ± 1.31% for maximum dose and 0.27% ± 0.79% for the PTV receiving 95% of the prescribed dose (V95). Furthermore, no significant difference was found for PTV volume (P = 0.50), the maximum dose (P = 0.83) and V95 (P = 0.19) between deepMTP and CTTP. Conclusions: We have developed an automated approach (deepMTP) that allows generation of a continuously valued pseudo CT from a single high‐resolution 3D MR image and evaluated it in partial brain tumor treatment planning. The deepMTP provided dose distribution with no significant difference relative to a kVCT‐based standard volumetric modulated arc therapy plans. [ABSTRACT FROM AUTHOR]

Radiotherapy is an integral component of head/neck squamous cell carcinomas (HNSCCs) treatment, and technological developments including advances in image-guided radiotherapy over the past decades have offered improvements in the technical treatment of these cancers. Integration of magnetic resonance imaging (MRI) into image guidance through the development of MR-guided radiotherapy (MRgRT) offers further potential for refinement of the techniques by which HNSCCs are treated. This article provides an overview of the literature supporting the current use of MRgRT for HNSCC, challenges with its use, and developing research areas. [ABSTRACT FROM AUTHOR]

Soft tissue sarcomas (STS) are a rare class of tumors that originate from mesenchymal tissues and occur most frequently in the extremities, trunk, and retroperitoneum. Surgical resection with R0 margins is the primary curative treatment for most localized STS. In this setting, radiation therapy is used either pre-operatively or post-operatively to reduce the rate of local recurrence. Modern pre- or post-operative radiation therapy rely on the use of MRI sequences to guide target delineation during treatment planning. MRI-guided radiotherapy also offers unique advantages over CT-guided approaches in differentiating STS from surrounding normal soft tissues and enabling better identification of target volumes on daily imaging. For patients with unresectable STS, radiation therapy may offer the best chance for local tumor control. However, most STS are relatively radioresistant with modest rates of local control achieved using conventionally fractionated radiation. Specialized techniques such as hypofractionated radiation may allow for dose intensification and may increase rates of local control for STS. In these settings, MRI becomes even more critical for the delineation of targets and organs at risk and management of tumor and organ at risk motion during and between radiotherapy treatment fractions. [ABSTRACT FROM AUTHOR]

Abstract: The purpose of this study was to evaluate helical tomotherapy dosimetry in postmastectomy patients undergoing treatment for chest wall and positive nodal regions with simultaneous integrated boost (SIB) in the scar region using strip bolus. Six postmastectomy patients were scanned with a 5-mm-thick strip bolus covering the scar planning target volume (PTV) plus 2-cm margin. For all 6 cases, the chest wall received a total cumulative dose of 49.3–50.4 Gy with daily fraction size of 1.7–2.0 Gy. Total dose to the scar PTV was prescribed to 58.0–60.2 Gy at 2.0–2.5 Gy per fraction. The supraclavicular PTV and mammary nodal PTV received 1.7–1.9 dose per fraction. Two plans (with and without bolus) were generated for all 6 cases. To generate no-bolus plans, strip bolus was contoured and overrode to air density before planning. The setup reproducibility and delivered dose accuracy were evaluated for all 6 cases. Dose-volume histograms were used to evaluate dose-volume coverage of targets and critical structures. We observed reduced air cavities with the strip bolus setup compared with what we normally see with the full bolus. The thermoluminescence dosimeters (TLD) in vivo dosimetry confirmed accurate dose delivery beneath the bolus. The verification plans performed on the first day megavoltage computed tomography (MVCT) image verified that the daily setup and overall dose delivery was within 2% accuracy compared with the planned dose. The hotspot of the scar PTV in no-bolus plans was 111.4% of the prescribed dose averaged over 6 cases compared with 106.6% with strip bolus. With a strip bolus only covering the postmastectomy scar region, we observed increased dose uniformity to the scar PTV, higher setup reproducibility, and accurate dose delivered beneath the bolus. This study demonstrates the feasibility of using a strip bolus over the scar using tomotherapy for SIB dosimetry in postmastectomy treatments. [Copyright &y& Elsevier]

Purpose: Tumor control probability (TCP)-based early regression index (ERITCP) is a radiobiological parameter that showed promising results in predicting pathologic complete response (pCR) on T2-weighted 1.5 T magnetic resonance (MR) images of patients with locally advanced rectal cancer. This study aims to validate the ERITCP in the context of low-tesla MR-guided radiation therapy, using images acquired with different magnetic field strength (0.35 T) and image contrast (T2/T1). Furthermore, the optimal timing for pCR prediction was estimated, calculating the ERI index at different biologically effective dose (BED) levels.Methods and Materials: Fifty-two patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation therapy were enrolled in this multi-institutional retrospective study. For each patient, a 0.35 T T2/T1-weighted MR image was acquired during simulation and on each treatment day. Gross tumor volume was contoured according to International Commission on Radiation Units Report 83 guidelines. According to the original definition, ERITCP was calculated considering the residual tumor volume at BED = 25 Gy. ERI was also calculated in correspondence with several BED levels: 13, 21, 32, 40, 46, 54, 59, and 67. The predictive performance of the different ERI indices were evaluated in terms of receiver operating characteristic curve. The robustness of ERITCP with respect to the interobserver variability was also evaluated considering 2 operators and calculating the intraclass correlation index.Results: Fourteen patients showed pCR. ERITCP correctly 47 of 52 cases (accuracy = 90%), showing good results in terms of sensitivity (86%), specificity (92%), negative predictive value (95%), and positive predictive value (80%). The analysis at different BED levels shows that the best predictive performance is obtained when this parameter is calculated at BED = 25 Gy (area under the curve = 0.93). ERITCP results are robust with respect to interobserver variability (intraclass correlation index = 0.99).Conclusions: This study confirmed the validity and the robustness of ERITCP as a pCR predictor in the context of low-tesla MR-guided radiation therapy and indicate 25 Gy as the best BED level to perform predictions. [ABSTRACT FROM AUTHOR]